Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Anlotinib Maintenance in ES-SCLC
NCT04363255Phase 2Unknown
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, anlotinib in small cell lung cancer (SCLC), sponsored by Taizhou Hospital of Zhejiang Province. Status: unknown.
02
Drugs
toripalimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04363255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363255.